Perspectives on Ensifentrine and Its Therapeutic Potential in the Treatment of COPD: Evidence to Date

Abstract

Ensifentrine is a novel inhalational phosphodiesterase (PDE)3 and PDE4 inhibitor which improves bronchodilation and decreases inflammatory markers by acting locally on the bronchial tissue, with minimal systemic effects. Both preclinical and clinical trials have demonstrated benefits of this therapy, including improvement in lung function and reduction in exacerbations. This therapy is currently under review by the US Food and Drug Administration with a decision expected in 2024.

Polymorphism, phase transition, and physicochemical property investigation of Ensifentrine

“…27–31 As a dual phosphodiesterase 3/4 inhibitor, it works by targeting the enzymes involved in regulating inflammatory responses and bronchoconstriction in the lungs. 32–36 By inhibiting these enzymes, ENSE can help reduce inflammation and relax the muscles in the airways, thus improving the airflow and the symptoms associated with COPD and other respiratory diseases. 27,37,38 Clinical trials are essential to further evaluate the safety and efficacy of ENSE in treating these conditions.…”